<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type='text/xsl' href='/ProjectMundo-Anon/style/jats-html.xsl'?>
<!DOCTYPE response>
<article article-type="research-article" dtd-version="1.2" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    41598
   </journal-id>
   <journal-id journal-id-type="doi">
    10.1038/41598.2045-2322
   </journal-id>
   <journal-title-group>
    <journal-title>
     Scientific Reports
    </journal-title>
    <abbrev-journal-title abbrev-type="publisher">
     Sci Rep
    </abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2045-2322
   </issn>
   <publisher>
    <publisher-name>
     Nature Publishing Group UK
    </publisher-name>
    <publisher-loc>
     London
    </publisher-loc>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">
    s41598-023-51013-3
   </article-id>
   <article-id pub-id-type="manuscript">
    51013
   </article-id>
   <article-id pub-id-type="doi">
    10.1038/s41598-023-51013-3
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Article
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/4019
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/617
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/617/375/1370/534
     </subject>
    </subj-group>
    <subj-group subj-group-type="NatureArticleTypeID">
     <subject>
      article
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">
     Matumizi ya pamoja ya anticoagulant na antiplatelet kwenye matokeo baada ya kiharusi kwa wagonjwa wenye atrial fibrillation isiyo ya valvular na atherosclerosis ya mfumo
    </article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" id="Au1">
     <name name-style="western">
      <surname>
       Heo
      </surname>
      <given-names>
       JoonNyung
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au2">
     <name name-style="western">
      <surname>
       Lee
      </surname>
      <given-names>
       Hyungwoo
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au3">
     <name name-style="western">
      <surname>
       Lee
      </surname>
      <given-names>
       Il Hyung
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au4">
     <name name-style="western">
      <surname>
       Lim
      </surname>
      <given-names>
       In Hwan
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au5">
     <name name-style="western">
      <surname>
       Hong
      </surname>
      <given-names>
       Soon-Ho
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au6">
     <name name-style="western">
      <surname>
       Shin
      </surname>
      <given-names>
       Joonggyeong
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au7">
     <name name-style="western">
      <surname>
       Nam
      </surname>
      <given-names>
       Hyo Suk
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
    </contrib>
    <contrib contrib-type="author" corresp="yes" id="Au8">
     <name name-style="western">
      <surname>
       Kim
      </surname>
      <given-names>
       Young Dae
      </given-names>
     </name>
     <address>
      <email>
       neuro05@yuhs.ac
      </email>
     </address>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="corresp" rid="IDs41598023510133_cor8">
      h
     </xref>
    </contrib>
    <aff id="Aff1">
     <label>
      1
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/01wjejq96
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.15444.30
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0470 5454
      </institution-id>
      <institution content-type="org-division">
       Department of Neurology
      </institution>
      <institution content-type="org-name">
       Yonsei University College of Medicine
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Seoul
     </addr-line>
     <country country="KR">
      South Korea
     </country>
    </aff>
    <aff id="Aff2">
     <label>
      2
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/01wjejq96
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.15444.30
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0470 5454
      </institution-id>
      <institution content-type="org-division">
       Department of Radiology
      </institution>
      <institution content-type="org-name">
       Yonsei University College of Medicine
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Seoul
     </addr-line>
     <country country="KR">
      South Korea
     </country>
    </aff>
   </contrib-group>
   <author-notes>
    <corresp id="IDs41598023510133_cor8">
     <label>
      h
     </label>
     <email>
      neuro05@yuhs.ac
     </email>
    </corresp>
   </author-notes>
   <pub-date date-type="pub" publication-format="electronic">
    <day>
     3
    </day>
    <month>
     1
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <pub-date date-type="collection" publication-format="electronic">
    <month>
     12
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <volume>
    14
   </volume>
   <issue seq="305">
    1
   </issue>
   <elocation-id>
    304
   </elocation-id>
   <history>
    <date date-type="registration">
     <day>
      29
     </day>
     <month>
      12
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="received">
     <day>
      4
     </day>
     <month>
      4
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="accepted">
     <day>
      29
     </day>
     <month>
      12
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="online">
     <day>
      3
     </day>
     <month>
      1
     </month>
     <year>
      2024
     </year>
    </date>
   </history>
   <permissions>
    <copyright-statement content-type="compact">
     © The Author(s) 2024
    </copyright-statement>
    <copyright-year>
     2024
    </copyright-year>
    <copyright-holder>
     The Author(s)
    </copyright-holder>
    <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
     <license-p>
      <bold>
       Open Access
      </bold>
      This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
      <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
       http://creativecommons.org/licenses/by/4.0/
      </ext-link>
      .
     </license-p>
    </license>
   </permissions>
   <abstract id="Abs1" xml:lang="en">
    <title>
     Muhtasari
    </title>
    <p id="Par1">
     Utafiti huu ulilenga kuchunguza kama kulikuwa na tofauti katika matokeo ya mwaka mmoja baada ya kiharusi kati ya wagonjwa waliotibiwa na antiplatelet na anticoagulation (OAC + antiplatelet) na wale waliotibiwa na anticoagulation pekee (OAC), wakati ugonjwa wa atherosclerotic ulipokuwepo pamoja na atrial fibrillation isiyo ya valvular (NVAF). Huu ulikuwa utafiti wa nyuma ukitumia kikundi cha mbele cha wagonjwa waliopata kiharusi cha ischemic. Wagonjwa wenye NVAF na ugonjwa wa atherosclerotic waliwekwa katika kundi la OAC + antiplatelet au OAC kulingana na dawa walizopewa wakati wa kutoka hospitalini. Vifo vyote, kiharusi cha ischemic kinachorudiwa, kiharusi cha hemorrhagic, mshtuko wa moyo, na matukio ya kutokwa na damu ndani ya mwaka mmoja baada ya kiharusi cha awali vililinganishwa. Kati ya wagonjwa 445 waliowekwa katika utafiti huu, 149 (33.5%) walitibiwa na OAC + antiplatelet. Hakukuwa na tofauti kubwa katika matokeo yote kati ya makundi. Baada ya uzito wa uwezekano wa matibabu kinyume, OAC + antiplatelet ilihusishwa na hatari ndogo ya vifo vyote (uwiano wa hatari 0.48; 95% interval ya kujiamini 0.23–0.98; P = 0.045) na mshtuko wa moyo (0% dhidi ya 3.0%, P &lt; 0.001). Hatari ya kiharusi cha hemorrhagic haikuwa tofauti kubwa (P = 0.123). OAC + antiplatelet ilihusishwa na hatari ndogo ya vifo vyote na mshtuko wa moyo lakini hatari iliyoongezeka ya kiharusi cha ischemic miongoni mwa wagonjwa wenye NVAF na magonjwa ya atherosclerotic ya mfumo.
    </p>
   </abstract>
   <kwd-group kwd-group-type="hierarchical" vocab="FoR" vocab-identifier="ANZSRC 2008">
    <kwd content-type="term" vocab-term-identifier="11">
     Medical and Health Sciences
    </kwd>
    <nested-kwd>
     <kwd content-type="term" vocab-term-identifier="1102">
      Cardiorespiratory Medicine and Haematology
     </kwd>
    </nested-kwd>
   </kwd-group>
   <funding-group>
    <award-group>
     <funding-source>
      <institution-wrap>
       <institution>
        Yonsei University College of Medicine
       </institution>
       <institution-id institution-id-type="doi" vocab="open-funder-registry">
        http://dx.doi.org/10.13039/501100008005
       </institution-id>
      </institution-wrap>
     </funding-source>
     <award-id award-type="FundRef grant">
      6-2022-0170
     </award-id>
     <principal-award-recipient>
      <name name-style="western">
       <surname>
        Kim
       </surname>
       <given-names>
        Young Dae
       </given-names>
      </name>
     </principal-award-recipient>
    </award-group>
    <award-group>
     <funding-source>
      <institution-wrap>
       <institution>
        Korea Health Industry Development Institute
       </institution>
       <institution-id institution-id-type="doi" vocab="open-funder-registry">
        http://dx.doi.org/10.13039/501100003710
       </institution-id>
      </institution-wrap>
     </funding-source>
     <award-id award-type="FundRef grant">
      RS-2023-00265497
     </award-id>
     <principal-award-recipient>
      <name name-style="western">
       <surname>
        Kim
       </surname>
       <given-names>
        Young Dae
       </given-names>
      </name>
     </principal-award-recipient>
    </award-group>
   </funding-group>
   <custom-meta-group>
    <custom-meta>
     <meta-name>
      publisher-imprint-name
     </meta-name>
     <meta-value>
      Nature Portfolio
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-issue-count
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-article-count
     </meta-name>
     <meta-value>
      305
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-pricelist-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-holder
     </meta-name>
     <meta-value>
      Springer Nature Limited
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-contains-esm
     </meta-name>
     <meta-value>
      Yes
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-year
     </meta-name>
     <meta-value>
      2023
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-month
     </meta-name>
     <meta-value>
      12
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-day
     </meta-name>
     <meta-value>
      29
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-product
     </meta-name>
     <meta-value>
      NonStandardArchiveJournal
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-grants-type
     </meta-name>
     <meta-value>
      OpenChoice
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      metadata-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      abstract-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodypdf-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodyhtml-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bibliography-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      esm-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      online-first
     </meta-name>
     <meta-value>
      false
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-file-reference
     </meta-name>
     <meta-value>
      BodyRef/PDF/41598_2023_Article_51013.pdf
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-type
     </meta-name>
     <meta-value>
      Typeset
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      target-type
     </meta-name>
     <meta-value>
      OnlinePDF
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-type
     </meta-name>
     <meta-value>
      OriginalPaper
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-primary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-collection
     </meta-name>
     <meta-value>
      Science (multidisciplinary)
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      open-access
     </meta-name>
     <meta-value>
      true
     </meta-value>
    </custom-meta>
   </custom-meta-group>
  </article-meta>
 </front>
 <body>
  <sec id="Sec1">
   <title>
    Utangulizi
   </title>
   <p id="Par2">
    Kigaga cha nyuzi za moyo kisicho na valvu (NVAF) ni chanzo cha kawaida zaidi cha kiharusi cha ischemic
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
    </sup>
    . Kinaongeza kwa kiasi kikubwa hatari ya kiharusi, na matokeo baada ya kiharusi kilichosababishwa na NVAF ni mabaya zaidi kuliko etiolojia nyingine yoyote ya kiharusi
    <sup>
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
    </sup>
    . Kwa kuzuia embolism ya mfumo ikijumuisha kiharusi cha ischemic, matumizi ya dawa ya kupunguza damu ya mdomo (OAC) kama vile wapinzani wa vitamini K (VKA) au dawa za kupunguza damu za moja kwa moja (DOAC) zinapendekezwa sana kwa wagonjwa wenye NVAF
    <sup>
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
    </sup>
    .
   </p>
   <p id="Par3">
    Atherosclerosis ya mfumo katika ubongo, moyo, na mishipa ya pembeni inaweza kuwepo kwa wagonjwa wenye NVAF
    <sup>
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
     ,
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
     ,
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
    </sup>
    . Zaidi ya hayo, kuwepo kwa atherosclerosis yoyote ya mfumo kwa wagonjwa wenye kiharusi na NVAF kunaleta hatari kubwa zaidi ya matukio ya mishipa katika vitanda vya mishipa sawa au tofauti, ikionyesha haja ya mikakati bora ya antithrombotic kwa wagonjwa hawa
    <sup>
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
    </sup>
    . Kuongeza antiplatelet na OAC inaweza kuwa chaguo kwa usimamizi wa wagonjwa hawa, ingawa mipango hii inaweza kusababisha hatari kubwa ya kutokwa na damu
    <sup>
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
     ,
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
    </sup>
    . Tafiti za hivi karibuni zilipendekeza kwamba rivaroxaban ya dozi ndogo ikichanganywa na aspirini inaweza kuboresha matokeo ya moyo na mishipa kati ya wagonjwa wenye ugonjwa wa kuziba mishipa ya moyo (CAOD) au magonjwa ya kuziba mishipa ya pembeni (PAOD), ambayo inapendekeza kwamba matumizi ya OAC na antiplatelet yanaweza kuwa na manufaa kwa usimamizi wa ugonjwa wa atherosclerotic na kiharusi na NVAF. Hata hivyo, kuna taarifa chache juu ya usimamizi bora wa kiharusi na NVAF na atherosclerosis ya mfumo inayosababishwa, ikijumuisha stenosis ya mishipa ya ndani au nje ya fuvu pamoja na CAOD au PAOD
    <sup>
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
     ,
     <xref ref-type="bibr" rid="CR10">
      10
     </xref>
    </sup>
    .
   </p>
   <p id="Par4">
    Utafiti huu ulilenga kuchunguza kama matumizi ya pamoja ya antiplatelet na OAC yanaweza kuathiri matokeo ndani ya mwaka 1 baada ya kiharusi cha awali kati ya wagonjwa wenye NVAF na atherosclerosis ya mfumo.
   </p>
  </sec>
  <sec id="Sec2" sec-type="results">
   <title>
    Matokeo
   </title>
   <sec id="Sec3">
    <title>
     Idadi ya Wanafunzi
    </title>
    <p id="Par5">
     Kati ya wagonjwa 6912 wenye kiharusi cha ischemic au TIA, wagonjwa 1353 ambao walikuwa wamegunduliwa awali au wapya na NVAF walichaguliwa. Baada ya kuwatenga wagonjwa 51 (3.8%) waliokufa wakati wa kulazwa hospitalini, 60 (4.4%) kwa kupoteza ufuatiliaji, 546 (40.3%) kwa kutokuwa na ushahidi wowote wa ugonjwa wa atherosclerotic, 223 (16.5%) kwa kutokuwa na dawa ya kupunguza damu iliyowekwa, na 28 (2.0%) kwa saratani inayofanya kazi, wagonjwa 445 walijumuishwa katika utafiti huu (Fig.
     <xref ref-type="fig" rid="Fig1">
      1
     </xref>
     ).
     <fig id="Fig1" position="float">
      <label>
       Figure 1
      </label>
      <caption xml:lang="en">
       <p>
        Chati ya mtiririko wa wagonjwa waliowekwa katika utafiti huu.
       </p>
      </caption>
      <graphic href="/ProjectMundo-Anon/MediaObjects/10X1038_s41598-023-51013-3/41598_2023_51013_Fig1_HTML.png" id="MO1" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec4">
    <title>
     Sifa za Msingi
    </title>
    <p id="Par6">
     Umri wa wastani ulikuwa miaka 75 (kiwango cha kati, IQR 70.0–80.0) na 59.3% (n = 264) walikuwa wanaume kati ya wagonjwa 445 waliowekwa. Kati ya wagonjwa hawa, 193 (43.4%) walikuwa na atherosclerosis ya ubongo, 278 (62.5%) walikuwa na CAOD, 13 (2.9%) walikuwa na PAOD, 74 (16.6%) walikuwa na atheroma ya upinde wa aorta, 62 (13.9%) walikuwa na stenti za moyo, na 12 (2.7%) walikuwa na stenti za mishipa ya ubongo. Kulikuwa na wagonjwa 293 (65.8%) wenye vidonda vya atherosclerotic katika kitanda kimoja cha mishipa, 121 (27.2%) katika vitanda viwili, 27 (6.1%) katika vitanda vitatu, na wanne (0.9%) katika vitanda vinne (Fig.
     <xref ref-type="fig" rid="Fig2">
      2
     </xref>
     na Jedwali la Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     ).
     <fig id="Fig2" position="float">
      <label>
       Figure 2
      </label>
      <caption xml:lang="en">
       <p>
        Usambazaji wa wagonjwa kwa kila ugonjwa wa atherosclerosis.
        <italic>
         CAOD
        </italic>
        ugonjwa wa kuziba kwa mishipa ya moyo,
        <italic>
         PAOD
        </italic>
        ugonjwa wa kuziba kwa mishipa ya pembeni.
       </p>
      </caption>
      <graphic href="/ProjectMundo-Anon/MediaObjects/10X1038_s41598-023-51013-3/41598_2023_51013_Fig2_HTML.png" id="MO2" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par7">
     Kulikuwa na wagonjwa 296 (66.5%) waliotumia OAC pekee na 149 (33.5%) waliotumia OAC + antiplatelet. Kati ya wagonjwa 296 waliotibiwa na OAC pekee, 103 (34.8%) walipokea VKA na 193 (65.2%) walipokea DOAC. Kati ya wagonjwa 149 waliopokea OAC + antiplatelet, 96.6% (n = 144) walipokea wakala mmoja wa antiplatelet. Aspirini ilikuwa antiplatelet iliyowekwa mara nyingi zaidi (n = 65, 43.6%), ikifuatiwa na clopidogrel (n = 63, 42.3%), triflusal (n = 11, 7.4%), cilostazol (n = 5, 3.4%), na mchanganyiko wa antiplatelet mbili (n = 5, 3.4%). VKA ilitolewa mara nyingi zaidi kuliko DOAC kwa wagonjwa katika kundi la OAC + antiplatelet (55.0% [82/149] kwa VKA na 45.0% [67/149] kwa DOAC). Kati ya wagonjwa waliopokea VKA, hakukuwa na tofauti kati ya uwiano wa kimataifa uliowekwa wakati wa kuondoka kati ya makundi mawili (2.3 [IQR 1.9–2.7] kwa kundi la OAC pekee na 2.4 [IQR 1.9–2.8] kwa kundi la OAC + antiplatelet, P = 0.585). Kati ya wagonjwa 260 waliopokea DOAC, dozi isiyotosha ya DOAC ilitumika kwa 10% (n = 26) na uwiano wa wagonjwa waliopokea dozi isiyotosha haukuwa tofauti kati ya makundi mawili (10.4% [20/193] kwa kundi la OAC pekee na 9.0% [6/67] kwa kundi la OAC + antiplatelet, P = 0.925). Statin ilitolewa wakati wa kuondoka kwa 97.3% (n = 433). Aidha, matibabu ya statin hayakuwa tofauti kati ya makundi mawili (98.0% [290/296] kwa kundi la OAC pekee na 96.0% [143/149] kwa kundi la OAC + antiplatelet, P = 0.358). Hakukuwa na tofauti kubwa za aina za kiharusi kulingana na Jaribio la Org 10,172 katika Matibabu ya Kiharusi cha Haraka kati ya makundi mawili ya utafiti (P = 0.137, Jedwali la Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      2
     </xref>
     ). Zaidi ya sababu mbili aina ilikuwa etiolojia ya kawaida kwa makundi yote mawili. Echocardiography ya transesophageal ilifanywa kwa 63.4% (n = 282) ya wagonjwa, ambayo haikuwa tofauti kati ya makundi mawili (65.2% [193/296] kwa kundi la OAC pekee na 59.7% [89/149] kwa kundi la OAC + antiplatelet, P = 0.305). Tulipokagua utunzaji wa mpango wa antithrombotic kwa kutumia mapitio ya chati za matibabu na/au msimbo wa kielektroniki wa dawa kwa wagonjwa 38, ambao taarifa za dawa zao zingeweza kukaguliwa wakati wa kifo wakati wa ufuatiliaji, mpango wa antithrombotic wakati wa kuondoka ulidumishwa kwa 81.6% (n = 31) ya wagonjwa.
    </p>
    <p id="Par8">
     Ikilinganishwa na OAC pekee, wagonjwa wanaopokea OAC + antiplatelet walikuwa na uwezekano mkubwa wa kuwa na shinikizo la damu, CAOD, na stenti za ubongo na moyo (Jedwali
     <xref ref-type="table" rid="Tab1">
      1
     </xref>
     ). Uchambuzi wa usawazishaji wa kurudi nyuma wa mambo mengi uliozingatia vigezo hivi vinne ulionyesha kuwa CAOD (uwiano wa uwezekano [OR] 1.71; 95% kipimo cha kujiamini [CI] 1.09–2.69; P = 0.019), stenti ya ubongo (OR 5.31; 95% CI 1.51–18.60; P = 0.009), na stenti ya moyo (OR 6.24; 95% CI 3.42–11.39; P &lt; 0.001) zilikuwa viashiria huru vya matumizi ya OAC + antiplatelet.
     <table-wrap id="Tab1">
      <label>
       Jedwali 1
      </label>
      <caption xml:lang="en">
       <p>
        Ulinganisho wa sifa za msingi kati ya wagonjwa waliopokea mchanganyiko wa antiplatelet na anticoagulation na anticoagulation pekee
        <bold>
         .
        </bold>
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" rowspan="2"/>
         <th align="left" colspan="3">
          <p>
           Makundi yasiyorekebishwa
          </p>
         </th>
         <th align="left" colspan="3">
          <p>
           Makundi yaliyorekebishwa
          </p>
         </th>
        </tr>
        <tr>
         <th align="left">
          <p>
           OAC + Antiplatelet
          </p>
          <p>
           (n = 149)
          </p>
         </th>
         <th align="left">
          <p>
           OAC
          </p>
          <p>
           (n = 296)
          </p>
         </th>
         <th align="left">
          <p>
           D (%)
          </p>
         </th>
         <th align="left">
          <p>
           OAC + Antiplatelet
          </p>
          <p>
           (n = 152.2)
          </p>
         </th>
         <th align="left">
          <p>
           OAC
          </p>
          <p>
           (n = 284.5)
          </p>
         </th>
         <th align="left">
          <p>
           D (%)
          </p>
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left">
          <p>
           Umri (&gt; 75 miaka)
          </p>
         </td>
         <td align="left">
          <p>
           76 (51.0)
          </p>
         </td>
         <td align="left">
          <p>
           131 (44.3)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           13.5
          </p>
         </td>
         <td align="left">
          <p>
           67.0 (44.0)
          </p>
         </td>
         <td align="left">
          <p>
           127.7 (44.9)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           1.7
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Jinsia (Mwanaume)
          </p>
         </td>
         <td align="left">
          <p>
           94 (63.1)
          </p>
         </td>
         <td align="left">
          <p>
           170 (57.4)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           11.5
          </p>
         </td>
         <td align="left">
          <p>
           86.1 (56.5)
          </p>
         </td>
         <td align="left">
          <p>
           167.7 (59.0)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           4.9
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Shinikizo la damu
          </p>
         </td>
         <td align="left">
          <p>
           135 (90.6)
          </p>
         </td>
         <td align="left">
          <p>
           246 (83.1)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           22.3
          </p>
         </td>
         <td align="left">
          <p>
           128.3 (84.3)
          </p>
         </td>
         <td align="left">
          <p>
           243.1 (85.5)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           3.3
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Kisukari
          </p>
         </td>
         <td align="left">
          <p>
           60 (40.3)
          </p>
         </td>
         <td align="left">
          <p>
           105 (35.5)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           9.9
          </p>
         </td>
         <td align="left">
          <p>
           57.8 (38.0)
          </p>
         </td>
         <td align="left">
          <p>
           109.4 (38.4)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.9
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Dyslipidemia
          </p>
         </td>
         <td align="left">
          <p>
           65 (22.0)
          </p>
         </td>
         <td align="left">
          <p>
           33 (22.1)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.5
          </p>
         </td>
         <td align="left">
          <p>
           37.8 (24.8)
          </p>
         </td>
         <td align="left">
          <p>
           63.9 (22.5)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           5.6
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           CAOD
          </p>
         </td>
         <td align="left">
          <p>
           106 (71.1)
          </p>
         </td>
         <td align="left">
          <p>
           172 (58.1)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           27.4
          </p>
         </td>
         <td align="left">
          <p>
           94.3 (62.)
          </p>
         </td>
         <td align="left">
          <p>
           178.2 (62.6)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           1.3
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           PAOD
          </p>
         </td>
         <td align="left">
          <p>
           3 (2.0)
          </p>
         </td>
         <td align="left">
          <p>
           10 (3.4)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           8.4
          </p>
         </td>
         <td align="left">
          <p>
           2.6 (1.7)
          </p>
         </td>
         <td align="left">
          <p>
           5.6 (2.0)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           2.0
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Mvutaji sigara wa sasa
          </p>
         </td>
         <td align="left">
          <p>
           22 (14.8)
          </p>
         </td>
         <td align="left">
          <p>
           38 (12.8)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           5.6
          </p>
         </td>
         <td align="left">
          <p>
           18.0 (11.8)
          </p>
         </td>
         <td align="left">
          <p>
           36.3 (12.8)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           2.8
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           CHF
          </p>
         </td>
         <td align="left">
          <p>
           17 (11.4)
          </p>
         </td>
         <td align="left">
          <p>
           20 (6.8)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           16.2
          </p>
         </td>
         <td align="left">
          <p>
           13.0 (8.5)
          </p>
         </td>
         <td align="left">
          <p>
           24.1 (8.5)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.2
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Stenti ya ubongo
          </p>
         </td>
         <td align="left">
          <p>
           8 (5.4)
          </p>
         </td>
         <td align="left">
          <p>
           4 (1.4)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           22.4
          </p>
         </td>
         <td align="left">
          <p>
           3.3 (2.2)
          </p>
         </td>
         <td align="left">
          <p>
           5.4 (1.9)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           1.9
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Stenti ya moyo
          </p>
         </td>
         <td align="left">
          <p>
           44 (29.5)
          </p>
         </td>
         <td align="left">
          <p>
           18 (6.1)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           64.2
          </p>
         </td>
         <td align="left">
          <p>
           19.9 (13.1)
          </p>
         </td>
         <td align="left">
          <p>
           33.7 (11.9)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           3.7
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           NIHSS ya awali (&gt; 4)
          </p>
         </td>
         <td align="left">
          <p>
           74 (49.7)
          </p>
         </td>
         <td align="left">
          <p>
           146 (49.3)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.7
          </p>
         </td>
         <td align="left">
          <p>
           77.5 (50.9)
          </p>
         </td>
         <td align="left">
          <p>
           141.1 (49.6)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           2.7
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           GFR ya chini
          </p>
         </td>
         <td align="left">
          <p>
           6 (4.0)
          </p>
         </td>
         <td align="left">
          <p>
           7 (2.4)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           9.4
          </p>
         </td>
         <td align="left">
          <p>
           4.9 (3.2)
          </p>
         </td>
         <td align="left">
          <p>
           10.3 (3.6)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           2.3
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Stenosis ya arteri ya ubongo
          </p>
         </td>
         <td align="left">
          <p>
           70 (47.0)
          </p>
         </td>
         <td align="left">
          <p>
           123 (41.6)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           10.9
          </p>
         </td>
         <td align="left">
          <p>
           67.2 (44.1)
          </p>
         </td>
         <td align="left">
          <p>
           120.6 (42.4)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           3.5
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Atheroma ya aorta
          </p>
         </td>
         <td align="left">
          <p>
           24 (16.1)
          </p>
         </td>
         <td align="left">
          <p>
           50 (16.9)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           2.1
          </p>
         </td>
         <td align="left">
          <p>
           22.2 (14.6)
          </p>
         </td>
         <td align="left">
          <p>
           42.9 (15.1)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           1.4
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Statin ya dozi kubwa
          </p>
         </td>
         <td align="left">
          <p>
           102 (68.5)
          </p>
         </td>
         <td align="left">
          <p>
           226 (76.4)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           17.7
          </p>
         </td>
         <td align="left">
          <p>
           111.8 (73.4)
          </p>
         </td>
         <td align="left">
          <p>
           212.3 (74.6)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           2.6
          </p>
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <p>
        Thamani zimewasilishwa kama nambari (%) kwa vigezo vya kategoria na wastani [kiwango cha kati] kwa vigezo vya kuendelea.
       </p>
       <p>
        <italic>
         CAOD
        </italic>
        ugonjwa wa kuziba kwa arteri ya moyo,
        <italic>
         PAOD
        </italic>
        ugonjwa wa kuziba kwa arteri ya pembeni,
        <italic>
         CHF
        </italic>
        kushindwa kwa moyo kwa muda mrefu,
        <italic>
         NIHSS
        </italic>
        kipimo cha kiharusi cha Taasisi za Kitaifa za Afya,
        <italic>
         GFR
        </italic>
        kiwango cha uchujaji wa glomeruli.
       </p>
      </table-wrap-foot>
     </table-wrap>
    </p>
   </sec>
   <sec id="Sec5">
    <title>
     Ulinganisho wa matokeo katika idadi ya wanafunzi wa awali
    </title>
    <p id="Par9">
     Wakati wa ufuatiliaji wa mwaka 1 (wastani, siku 365; IQR 321–365 siku), matokeo yote ya mchanganyiko ndani ya mwaka 1 yalitokea kwa wagonjwa 93 (20.9%). Kwa kila matokeo, kulikuwa na vifo vya sababu zote kwa 50 (11.2%), kiharusi cha ischemic kilichorudiwa kwa 16 (2.9%) (3 [0.7%] vifo na 13 [2.9%] visivyo vya vifo), mshtuko wa moyo kwa tano (1.1%) (3 [0.7%] vifo na 2 [0.4%] visivyo vya vifo), kiharusi cha hemorrhagic kwa nne (0.9%, vyote visivyo vya vifo), na matukio ya kutokwa na damu kwa 35 (7.9%) (1 [0.2%] vifo na 34 [7.6%] visivyo vya vifo) wagonjwa. Hakukuwa na tofauti katika viwango vya matokeo yote yaliyopangwa kati ya mipango ya antithrombotic (Jedwali
     <xref ref-type="table" rid="Tab2">
      2
     </xref>
     ).
     <table-wrap id="Tab2">
      <label>
       Jedwali 2
      </label>
      <caption xml:lang="en">
       <p>
        Uwiano wa hatari kwa maagizo ya mchanganyiko wa anticoagulant ya mdomo na antiplatelet kwenye matokeo.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" rowspan="2"/>
         <th align="left" colspan="4">
          <p>
           Makundi yasiyorekebishwa
          </p>
         </th>
         <th align="left" colspan="4">
          <p>
           Makundi yaliyorekebishwa
          </p>
         </th>
        </tr>
        <tr>
         <th align="left">
          <p>
           OAC + Antiplatelet
          </p>
          <p>
           (n = 149)
          </p>
         </th>
         <th align="left">
          <p>
           OAC
          </p>
          <p>
           (n = 296)
          </p>
         </th>
         <th align="left">
          <p>
           Uwiano wa hatari
          </p>
         </th>
         <th align="left">
          <p>
           Thamani ya P
          </p>
         </th>
         <th align="left">
          <p>
           OAC + Antiplatelet
          </p>
          <p>
           (n = 152.2)
          </p>
         </th>
         <th align="left">
          <p>
           OAC
          </p>
          <p>
           (n = 284.5)
          </p>
         </th>
         <th align="left">
          <p>
           Uwiano wa hatari
          </p>
         </th>
         <th align="left">
          <p>
           Thamani ya P
          </p>
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left">
          <p>
           Matokeo yote ya mchanganyiko
          </p>
         </td>
         <td align="left">
          <p>
           31 (20.8)
          </p>
         </td>
         <td align="left">
          <p>
           62 (20.9)
          </p>
         </td>
         <td align="left">
          <p>
           0.93 [0.60;1.45]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.750
          </p>
         </td>
         <td align="left">
          <p>
           29.6 (19.4)
          </p>
         </td>
         <td align="left">
          <p>
           60.2 (21.1)
          </p>
         </td>
         <td align="left">
          <p>
           0.91 [0.55;1.50]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.709
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Vifo vyote vya sababu
          </p>
         </td>
         <td align="left">
          <p>
           13 (8.7)
          </p>
         </td>
         <td align="left">
          <p>
           37 (12.5)
          </p>
         </td>
         <td align="left">
          <p>
           0.63 [0.33;1.20]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.159
          </p>
         </td>
         <td align="left">
          <p>
           9.3 (6.1)
          </p>
         </td>
         <td align="left">
          <p>
           34.6 (12.2)
          </p>
         </td>
         <td align="left">
          <p>
           0.48 [0.23;0.98]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.045
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Kifo cha moyo na mishipa
          </p>
         </td>
         <td align="left">
          <p>
           4 (2.7)
          </p>
         </td>
         <td align="left">
          <p>
           13 (4.4)
          </p>
         </td>
         <td align="left">
          <p>
           0.60 [0.19;1.83]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.365
          </p>
         </td>
         <td align="left">
          <p>
           2.3 (1.5)
          </p>
         </td>
         <td align="left">
          <p>
           12.1 (4.3)
          </p>
         </td>
         <td align="left">
          <p>
           0.34 [0.10;1.17]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.087
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Kiharusi cha ischemic (cha kufa, kisicho cha kufa)
          </p>
         </td>
         <td align="left">
          <p>
           10 (6.7)
          </p>
         </td>
         <td align="left">
          <p>
           9 (3.0)
          </p>
         </td>
         <td align="left">
          <p>
           2.19 [0.89;5.38]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.089
          </p>
         </td>
         <td align="left">
          <p>
           13.5 (8.8)
          </p>
         </td>
         <td align="left">
          <p>
           8.9 (3.1)
          </p>
         </td>
         <td align="left">
          <p>
           2.76 [1.03;7.40]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.044
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Mshtuko wa moyo (cha kufa, kisicho cha kufa)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0)
          </p>
         </td>
         <td align="left">
          <p>
           7 (2.4)
          </p>
         </td>
         <td align="left">
          <p>
           0.00 [0.00;Inf]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.998
          </p>
         </td>
         <td align="left">
          <p>
           0.0 (0.0)
          </p>
         </td>
         <td align="left">
          <p>
           8.4 (3.0)
          </p>
         </td>
         <td align="left">
          <p>
           0.00 [0.00;0.00]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           &lt; 0.001
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Kiharusi cha hemorrhagic (cha kufa, kisicho cha kufa)
          </p>
         </td>
         <td align="left">
          <p>
           3 (2.0)
          </p>
         </td>
         <td align="left">
          <p>
           1 (0.3)
          </p>
         </td>
         <td align="left">
          <p>
           5.99 [0.62;57.60]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.121
          </p>
         </td>
         <td align="left">
          <p>
           3.8 (2.5)
          </p>
         </td>
         <td align="left">
          <p>
           1.2 (0.4)
          </p>
         </td>
         <td align="left">
          <p>
           6.12 [0.61;60.91]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.123
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Kutokwa na damu (cha kufa, kisicho cha kufa)
          </p>
         </td>
         <td align="left">
          <p>
           13 (8.7)
          </p>
         </td>
         <td align="left">
          <p>
           21 (7.1)
          </p>
         </td>
         <td align="left">
          <p>
           1.12 [0.55;2.27]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.760
          </p>
         </td>
         <td align="left">
          <p>
           11.9 (7.8)
          </p>
         </td>
         <td align="left">
          <p>
           21.4 (7.5)
          </p>
         </td>
         <td align="left">
          <p>
           1.01 [0.46;2.21]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.982
          </p>
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <p>
        Thamani zimewakilishwa kama nambari (%) kwa matukio na uwiano wa hatari [mipaka ya kujiamini ya 95%]. Ni tukio la kwanza tu la kila matokeo wakati wa kipindi cha ufuatiliaji wa mwaka 1 lilijumuishwa.
       </p>
       <p>
        <italic>
         Inf
        </italic>
        isiyo na kikomo,
        <italic>
         MI
        </italic>
        mshtuko wa moyo.
       </p>
      </table-wrap-foot>
     </table-wrap>
    </p>
   </sec>
   <sec id="Sec6">
    <title>
     Ulinganisho wa matokeo katika idadi ya wanafunzi waliolinganishwa
    </title>
    <p id="Par10">
     Baada ya kufanya uzito wa uwezekano wa matibabu kinyume, sifa za msingi zilikuwa zimepimwa vizuri na ukubwa wa sampuli zilizopimwa wa 284.5 kwa kundi la OAC na 152.2 kwa kundi la OAC + antiplatelet (Jedwali
     <xref ref-type="table" rid="Tab1">
      1
     </xref>
     na Mchoro wa Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     ). Makadirio ya Kaplan–Meier yalionyesha kuwa matokeo yote ya mchanganyiko hayakutofautiana kulingana na mpango wa antithrombotic. Hata hivyo, OAC pekee ilikuwa na hatari kubwa ya kifo ndani ya mwaka 1 ikilinganishwa na OAC + antiplatelet (log-rank P = 0.045, Mchoro
     <xref ref-type="fig" rid="Fig3">
      3
     </xref>
     ). Uchambuzi wa Cox regression ulionyesha kuwa vifo vya sababu zote ndani ya mwaka 1 vilikuwa juu zaidi kwa wagonjwa waliopokea OAC pekee kuliko wale waliopokea OAC + antiplatelet (6.1% vs. 12.2%; uwiano wa hatari, 0.48; 95% CI 0.23–0.98; P = 0.045). Katika uchambuzi wa vikundi vidogo, athari ya matibabu ya OAC + antiplatelet kwenye vifo vya sababu zote ilikuwa thabiti kwa ujumla bila kujali sifa za msingi, wakati kulikuwa na mwingiliano kati ya aina ya antithrombotic na stenti ya ubongo, stenti ya moyo, au shinikizo la damu (Mchoro
     <xref ref-type="fig" rid="Fig4">
      4
     </xref>
     ). Matumizi ya OAC + antiplatelet pia yalihusishwa na hatari ndogo ya kifo cha moyo na mishipa (1.5% vs. 4.3%, P = 0.087) au mshtuko wa moyo (0% vs. 0.6%, P &lt; 0.001). Hata hivyo, kiharusi cha ischemic kilichorudiwa kilikuwa cha kawaida zaidi kwa wagonjwa waliopokea OAC + antiplatelet (8.8% vs. 3.1%; uwiano wa hatari, 2.76; 95% CI 1.03–7.40; P = 0.044) (Jedwali
     <xref ref-type="table" rid="Tab2">
      2
     </xref>
     ), na viharusi vingi vya ischemic vilivyokuwa vikirudiwa havikuwa vya vifo (Jedwali la Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      3
     </xref>
     ). Matokeo mengine yaliyopangwa, kama vile kiharusi cha hemorrhagic na matukio ya kutokwa na damu, hayakutofautiana kulingana na mpango wa antithrombotic.
     <fig id="Fig3" position="float">
      <label>
       Figure 3
      </label>
      <caption xml:lang="en">
       <p>
        Michoro ya Kaplan–Meier ya (
        <bold>
         A
        </bold>
        ) matokeo ya jumla, (
        <bold>
         B
        </bold>
        ) vifo vyote, (
        <bold>
         C
        </bold>
        ) mshtuko wa moyo, (
        <bold>
         D
        </bold>
        ) kiharusi cha ischemic, (
        <bold>
         E
        </bold>
        ) kiharusi cha hemorrhagic, na (
        <bold>
         F
        </bold>
        ) tukio la kutokwa na damu kwa kutumia mipango ya antithrombotic katika idadi ya watu waliolinganishwa.
       </p>
      </caption>
      <graphic href="/ProjectMundo-Anon/MediaObjects/10X1038_s41598-023-51013-3/41598_2023_51013_Fig3_HTML.png" id="MO3" mime-subtype="PNG" specific-use="web"/>
     </fig>
     <fig id="Fig4" position="float">
      <label>
       Figure 4
      </label>
      <caption xml:lang="en">
       <p>
        Uchambuzi wa vikundi vidogo vya wagonjwa waliopimwa kwa uzito wa uwezekano wa matibabu. Uwiano wa hatari wa Cox ulipatikana kwa kila kikundi kidogo. Mchanganyiko unaonyesha mchanganyiko wa antiplatelet na anticoagulation. Idadi ya vitanda vya mishipa ya damu ilifafanuliwa kama idadi ya magonjwa ya atherosclerotic ambayo mgonjwa alikuwa nayo, ambayo ni pamoja na stenosis ya mishipa ya ubongo, CAOD, PAOD, atheroma ya aorta, na historia ya kuingiza stenti za moyo na ubongo.
        <italic>
         CAOD
        </italic>
        ugonjwa wa kuziba mishipa ya moyo,
        <italic>
         PAOD
        </italic>
        ugonjwa wa kuziba mishipa ya pembeni,
        <italic>
         CHF
        </italic>
        kushindwa kwa moyo sugu,
        <italic>
         DOAC
        </italic>
        anticoagulants za mdomo za moja kwa moja,
        <italic>
         NIHSS
        </italic>
        kipimo cha kiharusi cha taasisi za kitaifa za afya,
        <italic>
         GFR
        </italic>
        kiwango cha uchujaji wa glomerular,
        <italic>
         HR
        </italic>
        uwiano wa hatari.
       </p>
      </caption>
      <graphic href="/ProjectMundo-Anon/MediaObjects/10X1038_s41598-023-51013-3/41598_2023_51013_Fig4_HTML.png" id="MO4" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
  </sec>
  <sec id="Sec7" sec-type="discussion">
   <title>
    Majadiliano
   </title>
   <p id="Par11">
    Utafiti huu ulichunguza kama matokeo ya mwaka mmoja yanaweza kutofautiana kulingana na mkakati wa antithrombotic baada ya kiharusi cha ischemic cha index miongoni mwa wagonjwa wenye NVAF na atherosclerosis ya mfumo. Ingawa matumizi ya pamoja ya OAC na tiba ya antiplatelet hayakuwa na athari ya manufaa katika idadi ya watu wa awali na hakukuwa na tofauti katika matokeo yote ya mchanganyiko katika idadi ya watu waliolinganishwa, uchambuzi wa uzito wa uwezekano wa matibabu kinyume ulionyesha kuwa hatari ya vifo vya sababu zote au mshtuko wa moyo ilikuwa chini kwa wagonjwa wenye matumizi ya pamoja ya OAC na antiplatelet wakati wagonjwa walikuwa na NVAF na atherosclerosis ya mfumo. Mwelekeo huu ulionekana kwa uthabiti katika vikundi mbalimbali, isipokuwa kwa wagonjwa wenye stenti za ubongo au moyo au shinikizo la damu. Hata hivyo, hatari ya kiharusi cha ischemic kilichorudiwa ilikuwa juu kwa wagonjwa wanaopokea tiba ya antiplatelet pamoja na OAC.
   </p>
   <p id="Par12">
    Atherosclerosis ya pamoja si nadra miongoni mwa wagonjwa wenye NVAF. Magonjwa ya atherosclerotic yanayokuwepo yanaweza kuonekana katika ama ateri ya carotid (hadi 64%), ateri ya moyo (17–38%), au ugonjwa wa ateri ya pembeni (6.7%)
    <sup>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
    </sup>
    . Katika utafiti huu, CAOD ilikuwa eneo la kawaida zaidi la atherosclerosis (63%) ikifuatiwa na atherosclerosis ya ubongo (43%). Zaidi ya hayo, takriban theluthi moja ya wagonjwa walikuwa na ugonjwa wa atherosclerotic na vitanda viwili au zaidi vya ateri. Aidha, ikiwa magonjwa yoyote ya atherosclerotic yapo, matokeo ya cerebro-cardiovascular yanaweza kuwa mabaya zaidi miongoni mwa wagonjwa wenye atrial fibrillation
    <sup>
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
     ,
     <xref ref-type="bibr" rid="CR13">
      13
     </xref>
     ,
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
    </sup>
    . Kwa hiyo, kuna wasiwasi kuhusu usimamizi wa wagonjwa wenye NVAF na atherosclerosis ya mfumo.
   </p>
   <p id="Par13">
    Kuzingatia hatari kubwa ya matukio ya moyo na mishipa miongoni mwa wagonjwa wenye NVAF na atherosclerosis inayokuwepo, mkakati wa matibabu wenye nguvu zaidi unahitajika. Hivi sasa, data juu ya mkakati bora wa antithrombotic kwa idadi hii maalum ni chache. Kwa sababu antiplatelets zinaweza kuzuia mkusanyiko wa platelet na kuzuia malezi ya thrombus chini ya hali ya mkazo wa juu na kasi ya juu, kuongeza antiplatelet kwa OAC inaweza kuwa na manufaa kwa wagonjwa wenye magonjwa ya atherothrombotic. Hata hivyo, matumizi ya pamoja ya antiplatelet na OAC kwa wagonjwa wenye NVAF ni changamoto kwa sababu tafiti za awali za kurudi nyuma na uchambuzi wa meta uliofuata ulionyesha kuwa faida ya antiplatelet na OAC kwa kuzuia matukio ya ischemic haikuonekana wazi au ilionekana tu katika hali maalum
    <sup>
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
    </sup>
    . Katika utafiti wetu, athari ya manufaa ya matumizi ya pamoja ya OAC na antiplatelet haikuonekana katika idadi ya watu wa awali wa utafiti, wakati faida ya mipango hii ilionekana kwa vifo vya sababu zote na mshtuko wa moyo baada ya kusawazisha sifa za msingi kwa kutumia uzito wa uwezekano wa matibabu kinyume. Hii inapendekeza kuwa sifa za mgonjwa au magonjwa ya pamoja yanaweza kuathiri ufanisi wa dawa, na uteuzi bora wa wagonjwa ambao wanapaswa kufaidika na OAC + antiplatelet utakuwa muhimu. Katika muktadha huu, uchunguzi zaidi juu ya idadi ya watu ambao wangefaidika na matumizi ya pamoja ya OAC na antiplatelet unahitajika.
   </p>
   <p id="Par14">
    Hata hivyo, kurudiwa kwa kiharusi cha ischemic kulikuwa juu kwa wale waliopangiwa OAC + antiplatelet, ingawa viharusi vingi vya ischemic vilivyotokea tena kwenye tiba ya OAC + antiplatelet wakati wa ufuatiliaji havikuonekana kuwa kali au vya hatari katika utafiti wetu. Hii inaashiria kwamba matumizi ya pamoja ya mpango wa antithrombotic hayangekuwa na ufanisi mkubwa katika kuzuia kurudiwa kwa kiharusi cha ischemic kuliko matumizi ya OAC pekee. Hatari ya kiharusi na ukali wake kwa wagonjwa wenye NVAF huathiriwa na nguvu ya VKA au kipimo cha DOAC
    <sup>
     <xref ref-type="bibr" rid="CR15">
      15
     </xref>
     ,
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
    </sup>
    . Madaktari wanaweza kusita kutumia kipimo bora cha DOAC au kudumisha nguvu ya matibabu ya VKA wakati wa ufuatiliaji kwa sababu ya wasiwasi kuhusu hatari ya kutokwa na damu, ingawa hatukuweza kuchunguza nguvu ya OAC wakati wa ufuatiliaji. Zaidi ya hayo, ikizingatiwa kuwa hatari ya matukio ya moyo na mishipa huongezeka na ongezeko la mzigo wa stenosis ya ubongo, kuongeza antiplatelet na OAC huenda hakutoshi kuzuia kurudiwa kwa kiharusi cha ischemic. Matokeo haya yanapendekeza kuwa mbinu ya matibabu yenye nguvu zaidi inahitajika ili kuzuia viharusi vinavyorudiwa katika idadi hii ya watu. Kwa mfano, sababu za hatari za mishipa kama vile shinikizo la damu, dyslipidemia, na kisukari ni viashiria vinavyojulikana vya thromboembolism inayosababishwa na atrial fibrillation na magonjwa ya atherosclerotic, na udhibiti mkali wa sababu za hatari za mishipa wakati wa ufuatiliaji utasaidia
    <sup>
     <xref ref-type="bibr" rid="CR17">
      17
     </xref>
     <xref ref-type="bibr" rid="CR18">
      18
     </xref>
     ,
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     ,
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
    </sup>
    .
   </p>
   <p id="Par15">
    Wakati wa kutumia OAC na antiplatelet, wasiwasi juu ya ongezeko la hatari ya matatizo ya kutokwa na damu huibuka
    <sup>
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
    </sup>
    . Matumizi ya pamoja ya antiplatelet na OAC yaliongeza hatari ya kutokwa na damu (hasa kwenye eneo la utumbo au ndani ya fuvu) ikilinganishwa na OAC pekee
    <sup>
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
    </sup>
    . Hata hivyo, katika utafiti wetu, ingawa kutokwa na damu kwenye ubongo kulionekana kuwa mara kwa mara katika kesi ya OAC + antiplatelet, hakukuwa na tofauti kubwa katika matatizo ya kutokwa na damu kati ya OAC + antiplatelet na OAC pekee. Matatizo ya kutokwa na damu yalikuwa na uwezekano mdogo wa kutokea wakati wa kutumia DOAC na antiplatelet, badala ya VKA na antiplatelet au kutumia OAC na antiplatelet moja badala ya OAC na antiplatelet mbili
    <sup>
     <xref ref-type="bibr" rid="CR22">
      22
     </xref>
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
    </sup>
    . Kwa wagonjwa wetu wanaotumia OAC + antiplatelet, wakala mmoja wa antiplatelet ulitumiwa zaidi na wagonjwa wengi walitibiwa na DOAC. Zaidi ya hayo, udhibiti mkali wa sababu za hatari za mishipa wakati wa ufuatiliaji ulifuatiliwa mara kwa mara katika kituo chetu cha kiharusi. Haya yanaweza kuhusiana na matokeo yetu.
   </p>
   <p id="Par16">
    Utafiti wetu una mapungufu kadhaa. Katika utafiti huu, tuligawanya idadi ya watu waliotafitiwa kulingana na dawa wakati wa kuondoka hospitalini. Ingawa dawa wakati wa ufuatiliaji ilionekana kudumishwa vizuri baada ya kuondoka hospitalini, hatukuweza kutathmini utiifu au nguvu ya mawakala wa antithrombotic kikamilifu. Ingawa uwekaji uzito wa uwezekano wa matibabu, mbinu ya takwimu iliyothibitishwa kutathmini athari za matibabu tofauti kwa kutumia data ya nyuma, ilifanywa ili kuondoa upendeleo wa uteuzi kwa tiba ya antithrombotic, kunaweza kuwa na mambo mengine ambayo hatukuzingatia. Tulichunguza tu matokeo ya mwaka 1 baada ya kiharusi cha awali; kwa hivyo, matokeo haya hayakuashiria faida yoyote ya matumizi ya muda mrefu ya OAC + antiplatelet. Ikizingatiwa kuwa seti ya data ilikuwa kutoka kituo kimoja, pamoja na asili ya nyuma ya utafiti, kunaweza kuwa na upendeleo wa uteuzi katika seti ya data. Tafiti za udhibiti wa nasibu zinapaswa kufanywa ili kuondoa upendeleo wa uteuzi kati ya makundi mawili
    <sup>
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
    </sup>
    .
   </p>
  </sec>
  <sec id="Sec8" sec-type="methods">
   <title>
    Mbinu
   </title>
   <sec id="Sec9">
    <title>
     Wagonjwa
    </title>
    <p id="Par17">
     Huu ulikuwa utafiti wa nyuma ukitumia data kutoka kwa utafiti wa kikundi cha uchunguzi wa hospitali (Clinicaltrials.gov NCT03510312) ukichunguza utabiri wa muda mrefu wa wagonjwa wenye kiharusi cha ischemic au shambulio la ischemic la muda (TIA) ambao walilazwa katika Kituo cha Kiharusi cha Severance kilichopo Seoul, Jamhuri ya Korea. Kikundi hiki kilijumuisha wagonjwa wenye infarction ya ubongo wa papo hapo au TIA ndani ya siku 7 za kuanza ambao walilazwa kati ya Januari 1, 2012, na Desemba 31, 2020. Wagonjwa wote walifanyiwa CT ya ubongo na/au picha ya sumaku ya mwili pamoja na angiografia, ikiwa ni pamoja na angiografia ya CT, angiografia ya sumaku ya mwili, au angiografia ya kuondoa dijiti. Wakati wa kulazwa hospitalini, wagonjwa wote walitathminiwa kwa kina na kwa kina ili kubaini data zao za kidemografia, historia ya matibabu, maonyesho ya kliniki, sababu za hatari za mishipa, na magonjwa yanayoambatana. Wagonjwa pia walifanyiwa vipimo vya kawaida vya damu, elektrokardiografia ya 12-lead, na ufuatiliaji wa Holter. Karibu wagonjwa wote walilazwa katika kitengo cha kiharusi na kufuatiliwa mfululizo kwa kutumia elektrokardiografia wakati wa kukaa kwao (wastani, siku 5; IQR 4-6 siku). Echocardiografia, ikiwa ni pamoja na echocardiografia ya transesophageal, ilikuwa uchunguzi wa kawaida isipokuwa haikuweza kufanywa kwa sababu ya hali ya mgonjwa au kushindwa kupata idhini ya habari. Utafiti huu uliidhinishwa na Bodi ya Mapitio ya Taasisi ya Chuo cha Tiba cha Chuo Kikuu cha Yonsei (nambari ya idhini: 4-2022-1098) na msamaha wa idhini ya habari kutokana na asili ya nyuma ya utafiti. Mbinu zote katika utafiti wetu zilifanywa kwa mujibu wa kanuni za Azimio la Helsinki.
    </p>
   </sec>
   <sec id="Sec10">
    <title>
     Vigezo vya Kliniki
    </title>
    <p id="Par18">
     Kwa kila mgonjwa, data za kidemografia, sababu za hatari za mishipa, na magonjwa yanayoambatana ikiwa ni pamoja na shinikizo la damu, kisukari mellitus, dyslipidemia, CAOD, PAOD, na historia ya kiharusi zilikusanywa. Uvutaji sigara wa sasa (sigara moja au zaidi iliyovutwa katika mwezi uliopita) na hali ya matumizi ya pombe pia zilipimwa. Ukali wa kiharusi ulitathminiwa kwa kutumia Kiwango cha Kiharusi cha Taasisi za Kitaifa za Afya (NIHSS). Ulemavu wa awali ulifafanuliwa kama alama ya Kiwango cha Rankin kilichobadilishwa (mRS) ya 2-5 kabla ya kiharusi cha awali. Aina za kiharusi ziliorodheshwa kulingana na Uainishaji wa Jaribio la Org 10172 katika Uainishaji wa Matibabu ya Kiharusi cha Papo hapo
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
     </sup>
     . Kadirio la uchujaji wa glomerular lilihesabiwa kwa kutumia mbinu ya CKD-EPI. Data juu ya dawa za statin zilizowekwa wakati wa kuondoka hospitalini pia zilikusanywa. Tiba ya statin yenye nguvu kubwa ilifafanuliwa kama atorvastatin &gt; 40 mg au rosuvastatin &gt; 20 mg
     <sup>
      <xref ref-type="bibr" rid="CR26">
       26
      </xref>
     </sup>
     .
    </p>
    <p id="Par19">
     Idadi ya watu waliotafitiwa iligawanywa kulingana na mpango wa antithrombotic uliowekwa wakati wa kuondoka hospitalini: OAC pekee dhidi ya OAC na antiplatelet kwa pamoja. OAC ilijumuisha VKA na DOAC, ikiwa ni pamoja na dabigatran, rivaroxaban, apixaban, na edoxaban. Wakala wa antiplatelet walijumuisha aspirin, clopidogrel, cilostazol, triflusal, prasugrel, ticlopidine, na aggrenox.
    </p>
   </sec>
   <sec id="Sec11">
    <title>
     Kidonda cha atherosclerosis ya mfumo
    </title>
    <p id="Par20">
     Uwepo wa vidonda vya atherosclerotic katika mishipa ya aorta, ubongo, moyo, na mishipa ya pembeni ulifanyiwa uchunguzi kwa kila mgonjwa. Hii ilijumuisha moja au zaidi ya magonjwa yafuatayo ya atherosclerotic: (1) atherosclerosis ya ubongo na stenosis &gt; 50% kulingana na mbinu ya North American Symptomatic Carotid Endarterectomy Trial kwa ajili ya mishipa ya nje ya fuvu au Warfarin dhidi ya Aspirin kwa mbinu ya Symptomatic Intracranial Disease kwa mishipa ya ndani ya fuvu; (2) atheroma ya aorta &gt; 4 mm katika aorta inayopanda au upinde wa aorta kwenye transesophageal echocardiography; (3) historia ya awali ya CAOD au PAOD; na (4) uwekaji wa stenti ya moyo au carotid. Ili kuzuia tafsiri potofu ya kuziba kwa embolic kama atherosclerosis ya ubongo, tulijumuisha tu vidonda vya stenotic baada ya kuondoa vidonda vya mishipa katika maeneo yaliyoathirika au kuziba kabisa kwa mshipa wa ubongo. CAOD ilifafanuliwa kama (1) historia ya awali ya mshtuko wa moyo au angina isiyo imara na (2) stenosis ya mishipa ya moyo, iwe na dalili au bila dalili, kwenye angiografia ya catheter ya moyo iliyothibitishwa au CT ya moyo ya multidetector. Uwepo wa PAOD ulifafanuliwa wakati ulithibitishwa na tathmini ya sonografia au angiografia ya CT. Mzigo wa atherosclerosis ya mfumo ulitathminiwa kama jumla ya idadi ya magonjwa ya atherosclerotic ikiwa ni pamoja na stenosis ya mishipa ya ubongo, CAOD, PAOD, atheroma ya aorta, na historia ya uwekaji wa stenti ya moyo au ubongo
     <sup>
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec12">
    <title>
     Vipimo vya Matokeo
    </title>
    <p id="Par21">
     Katika kituo chetu cha kiharusi, wataalamu wa neva wa kiharusi na wauguzi wa utafiti walikuwa wakikutana na wagonjwa au walezi wao mara kwa mara kupitia ziara za ana kwa ana au mahojiano ya simu na au bila mapitio ya chati za matibabu ili kuchunguza maendeleo ya matukio ya mishipa, saratani, au sababu za hatari zilizogunduliwa wakati wa ufuatiliaji. Wagonjwa waliowekwa katika utafiti huu walifuatiliwa mara kwa mara kwa miezi 3 na mwaka 1 baada ya kuruhusiwa.
    </p>
    <p id="Par22">
     Wakati mgonjwa alipokufa, tulirekodi tarehe na ikiwezekana, sababu ya kifo ilibainishwa. Kifo cha moyo na mishipa kilifafanuliwa kama kifo kinachotokana na mshtuko wa moyo, kifo cha ghafla cha moyo, kushindwa kwa moyo, utaratibu wa moyo na mishipa, au kiharusi
     <sup>
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
     </sup>
     . Pia tulikusanya data juu ya kutokea kwa kiharusi cha ischemic kinachorudiwa (ikiwa ni pamoja na TIA), kiharusi cha hemorrhagic, mshtuko wa moyo, au matukio ya kutokwa na damu ndani ya mwaka 1 baada ya kiharusi na ikiwa ipo, tarehe ya matukio. Kiharusi cha ischemic kinachorudiwa kilibainishwa na mtaalamu wa kiharusi kulingana na matokeo ya kliniki na radiolojia. Kiharusi cha hemorrhagic kilijumuisha kutokwa na damu ndani ya ubongo, ndani ya ventrikali, subarachnoid, na subdural. Mshtuko wa moyo ulifafanuliwa kama utambuzi wa mshtuko wa moyo mkali kulingana na dalili za kliniki, vimeng'enya vya moyo, electrocardiography, na tafiti za picha, kama vile angiografia ya moyo. Matukio yote ya kutokwa na damu yalirekodiwa, ikiwa ni pamoja na kiharusi cha hemorrhagic, kutokwa na damu kwa njia ya utumbo, kutokwa na damu kwa njia ya upumuaji, na kutokwa na damu kwa misuli inayohitaji kuongezewa damu au kulazwa hospitalini. Kiharusi cha ischemic kinachoua, kiharusi cha hemorrhagic kinachoua, mshtuko wa moyo unaoua, na matukio ya kutokwa na damu yanayoua yalifafanuliwa kama kifo baada ya ugonjwa mkali husika bila sababu nyingine yoyote dhahiri ya kifo, ambayo iliamuliwa na daktari
     <sup>
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
     </sup>
     . Matokeo ya msingi ya utafiti huu yalikuwa matokeo yote ya mchanganyiko ndani ya mwaka 1 wa kiharusi cha awali. Tulilinganisha matokeo haya yaliyopangwa mapema ndani ya mwaka 1 wa kiharusi cha awali kulingana na dawa.
    </p>
   </sec>
   <sec id="Sec13">
    <title>
     Uchambuzi wa Takwimu
    </title>
    <p id="Par23">
     Tabia za msingi za washiriki wa utafiti zililinganishwa. Vigezo endelevu vililinganishwa kwa kutumia mtihani wa Mann–Whitney
     <italic>
      U
     </italic>
     , na vigezo vya kategoria kwa kutumia mtihani wa chi-square wa Pearson. Ili kupata sababu huru ya matumizi ya antiplatelet pamoja na OAC, vigezo vilivyohusishwa kwa kiasi kikubwa na kundi la OAC + antiplatelet vilichaguliwa. Kwa kutumia vigezo hivi, uchambuzi wa kurudi nyuma wa kimantiki wa vigezo vingi ulifanywa ili hatimaye kupata uwiano wa uwezekano kwa kila kigezo.
    </p>
    <p id="Par24">
     Ili kurekebisha tofauti kubwa katika tabia za msingi kati ya makundi ya OAC pekee na OAC + antiplatelet, uzito wa uwezekano wa matibabu ulio kinyume ulifanywa. Alama za mwelekeo zilipimwa kwa wagonjwa wote waliojiandikisha katika utafiti huu kwa kutumia kurudi nyuma kwa kimantiki. Vichanganyaji vilivyochaguliwa vilikuwa umri mkubwa (&gt; miaka 75), jinsia, shinikizo la damu, kisukari, dyslipidemia, uvutaji sigara wa sasa, kushindwa kwa moyo, alama ya awali ya NIHSS ya juu (&gt; 4), kiwango cha chini cha uchujaji wa glomerular (
    </p>
    <p id="Par25">
     Makadirio ya Kaplan–Meier ya kuishi na mtihani wa log-rank yalitumiwa kulinganisha tofauti katika viwango vya matukio ya matokeo kati ya makundi ya OAC pekee na OAC + antiplatelet. Uchambuzi wa Cox wa uwiano wa hatari ulifanywa kulinganisha matokeo kati ya makundi ya matibabu. Thamani zote za
     <italic>
      P
     </italic>
     zilikuwa za pande mbili. Toleo la R 4.0 (R Core Team, Vienna, Austria) lilitumika kwa uchambuzi wa takwimu
     <sup>
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
     </sup>
     . Uzito wa uwezekano wa matibabu ulio kinyume ulifanywa kwa kutumia kifurushi cha "PSWeight" na uchambuzi wa kuishi kwa kutumia kifurushi cha "survival"
     <sup>
      <xref ref-type="bibr" rid="CR32">
       32
      </xref>
      ,
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
     </sup>
     .
    </p>
   </sec>
  </sec>
 </body>
 <back>
  <ack>
   <title>
    Shukrani
   </title>
   <p>
    Utafiti huu uliungwa mkono na ruzuku ya utafiti wa kitivo cha Chuo cha Tiba cha Chuo Kikuu cha Yonsei (6-2022-0170) na ruzuku kutoka kwa Mradi wa Korea wa Teknolojia ya Afya R&amp;D kupitia Taasisi ya Maendeleo ya Viwanda vya Afya ya Korea (KHIDI), iliyofadhiliwa na Wizara ya Afya na Ustawi, Jamhuri ya Korea (RS-2023-00265497).
   </p>
  </ack>
  <sec sec-type="author-contribution">
   <title>
    Mchango wa waandishi
   </title>
   <p>
    J.H. alifanya uchambuzi, aliandika, na kurekebisha maandiko makuu. H.L., I.H.L., I.H.L., na S.H.H. walifanya jukumu kubwa katika maandalizi ya data. J.S. alishiriki katika maandalizi ya data na sehemu ya uchambuzi wa takwimu. H.S.N. alirekebisha maandiko. Y.D.K. alibuni utafiti, alisimamia uchambuzi, aliandika, na kurekebisha maandiko makuu.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Upatikanaji wa Data
   </title>
   <p>
    The data supporting the findings of this study are available from the corresponding author on reasonable request.
   </p>
  </sec>
  <sec sec-type="ethics-statement">
   <sec id="FPar1" sec-type="COI-statement">
    <title>
     Maslahi Yanayokinzana
    </title>
    <p id="Par26">
     The authors declare no competing interests.
    </p>
   </sec>
  </sec>
  <ref-list id="Bib1">
   <title>
    Marejeleo
   </title>
   <ref-list>
    <ref id="CR1">
     <label>
      1.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Friberg
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       High prevalence of atrial fibrillation among patients with ischemic stroke
      </article-title>
      <source>
       Stroke
      </source>
      <year>
       2014
      </year>
      <volume>
       45
      </volume>
      <fpage>
       2599
      </fpage>
      <lpage>
       2605
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC2cXhsVGgsr7F
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1161/STROKEAHA.114.006070
      </pub-id>
      <pub-id pub-id-type="pmid">
       25034713
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR2">
     <label>
      2.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lin
        </surname>
        <given-names>
         HJ
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Stroke severity in atrial fibrillation: The Framingham study
      </article-title>
      <source>
       Stroke
      </source>
      <year>
       1996
      </year>
      <volume>
       27
      </volume>
      <fpage>
       1760
      </fpage>
      <lpage>
       1764
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DyaK28vjvV2qsg%3D%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1161/01.str.27.10.1760
      </pub-id>
      <pub-id pub-id-type="pmid">
       8841325
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR3">
     <label>
      3.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kleindorfer
        </surname>
        <given-names>
         DO
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association
      </article-title>
      <source>
       Stroke
      </source>
      <year>
       2021
      </year>
      <volume>
       52
      </volume>
      <fpage>
       e364
      </fpage>
      <lpage>
       e467
      </lpage>
      <pub-id pub-id-type="doi">
       10.1161/STR.0000000000000375
      </pub-id>
      <pub-id pub-id-type="pmid">
       34024117
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR4">
     <label>
      4.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sun
        </surname>
        <given-names>
         W
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Clinical and imaging characteristics of cerebral infarction in patients with nonvalvular atrial fibrillation combined with cerebral artery stenosis
      </article-title>
      <source>
       J. Atheroscler. Thromb.
      </source>
      <year>
       2018
      </year>
      <volume>
       25
      </volume>
      <fpage>
       720
      </fpage>
      <lpage>
       732
      </lpage>
      <pub-id pub-id-type="doi">
       10.5551/jat.43240
      </pub-id>
      <pub-id pub-id-type="pmid">
       29877196
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6099075
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR5">
     <label>
      5.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lehtola
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Stroke recurrence in patients with atrial fibrillation: Concomitant carotid artery stenosis doubles the risk
      </article-title>
      <source>
       Eur. J. Neurol.
      </source>
      <year>
       2017
      </year>
      <volume>
       24
      </volume>
      <fpage>
       719
      </fpage>
      <lpage>
       725
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC1czosFyisw%3D%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1111/ene.13280
      </pub-id>
      <pub-id pub-id-type="pmid">
       28317289
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR6">
     <label>
      6.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Zhou
        </surname>
        <given-names>
         G
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Cerebral arteriosclerosis stenosis predicts poor short-term prognosis in non-valvular atrial fibrillation related cardioembolic stroke treated by reperfusion therapy
      </article-title>
      <source>
       Clin. Neurol. Neurosurg.
      </source>
      <year>
       2021
      </year>
      <volume>
       207
      </volume>
      <fpage>
       106738
      </fpage>
      <pub-id pub-id-type="doi">
       10.1016/j.clineuro.2021.106738
      </pub-id>
      <pub-id pub-id-type="pmid">
       34147840
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR7">
     <label>
      7.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Chang
        </surname>
        <given-names>
         YJ
        </given-names>
       </name>
       <name>
        <surname>
         Ryu
        </surname>
        <given-names>
         SJ
        </given-names>
       </name>
       <name>
        <surname>
         Lin
        </surname>
        <given-names>
         SK
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Carotid artery stenosis in ischemic stroke patients with nonvalvular atrial fibrillation
      </article-title>
      <source>
       Cerebrovasc. Dis.
      </source>
      <year>
       2002
      </year>
      <volume>
       13
      </volume>
      <fpage>
       16
      </fpage>
      <lpage>
       20
      </lpage>
      <pub-id pub-id-type="doi">
       10.1159/000047740
      </pub-id>
      <pub-id pub-id-type="pmid">
       11810005
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR8">
     <label>
      8.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Dentali
        </surname>
        <given-names>
         F
        </given-names>
       </name>
       <name>
        <surname>
         Douketis
        </surname>
        <given-names>
         JD
        </given-names>
       </name>
       <name>
        <surname>
         Lim
        </surname>
        <given-names>
         W
        </given-names>
       </name>
       <name>
        <surname>
         Crowther
        </surname>
        <given-names>
         M
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: A meta-analysis of randomized trials
      </article-title>
      <source>
       Arch. Intern. Med.
      </source>
      <year>
       2007
      </year>
      <volume>
       167
      </volume>
      <fpage>
       117
      </fpage>
      <lpage>
       124
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD2sXhvFKms7w%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1001/archinte.167.2.117
      </pub-id>
      <pub-id pub-id-type="pmid">
       17242311
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR9">
     <label>
      9.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Eikelboom
        </surname>
        <given-names>
         JW
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Rivaroxaban with or without aspirin in stable cardiovascular disease
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2017
      </year>
      <volume>
       377
      </volume>
      <fpage>
       1319
      </fpage>
      <lpage>
       1330
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC2sXhs1Git7jN
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa1709118
      </pub-id>
      <pub-id pub-id-type="pmid">
       28844192
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR10">
     <label>
      10.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bonaca
        </surname>
        <given-names>
         MP
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Rivaroxaban in peripheral artery disease after revascularization
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2020
      </year>
      <volume>
       382
      </volume>
      <fpage>
       1994
      </fpage>
      <lpage>
       2004
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhtVeksrbI
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa2000052
      </pub-id>
      <pub-id pub-id-type="pmid">
       32222135
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR11">
     <label>
      11.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Chen
        </surname>
        <given-names>
         LY
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Atrial fibrillation burden: Moving beyond atrial fibrillation as a binary entity: A scientific statement from the American Heart Association
      </article-title>
      <source>
       Circulation
      </source>
      <year>
       2018
      </year>
      <volume>
       137
      </volume>
      <fpage>
       e623
      </fpage>
      <lpage>
       e644
      </lpage>
      <pub-id pub-id-type="doi">
       10.1161/CIR.0000000000000568
      </pub-id>
      <pub-id pub-id-type="pmid">
       29661944
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8463258
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR12">
     <label>
      12.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Investigators
        </surname>
        <given-names>
         A
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Baseline characteristics of patients with atrial fibrillation: The AFFIRM Study
      </article-title>
      <source>
       Am. Heart J.
      </source>
      <year>
       2002
      </year>
      <volume>
       143
      </volume>
      <fpage>
       991
      </fpage>
      <lpage>
       1001
      </lpage>
      <pub-id pub-id-type="doi">
       10.1067/mhj.2002.122875
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR13">
     <label>
      13.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Zhu
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Tan
        </surname>
        <given-names>
         X
        </given-names>
       </name>
       <name>
        <surname>
         Zhou
        </surname>
        <given-names>
         JZ
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A systematic review and meta-analysis
      </article-title>
      <source>
       Clin. Cardiol.
      </source>
      <year>
       2021
      </year>
      <volume>
       44
      </volume>
      <fpage>
       1050
      </fpage>
      <lpage>
       1057
      </lpage>
      <pub-id pub-id-type="doi">
       10.1002/clc.23678
      </pub-id>
      <pub-id pub-id-type="pmid">
       34170015
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8364730
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR14">
     <label>
      14.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hillerson
        </surname>
        <given-names>
         D
        </given-names>
       </name>
       <name>
        <surname>
         Wool
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <name>
        <surname>
         Ogunbayo
        </surname>
        <given-names>
         GO
        </given-names>
       </name>
       <name>
        <surname>
         Sorrell
        </surname>
        <given-names>
         VL
        </given-names>
       </name>
       <name>
        <surname>
         Leung
        </surname>
        <given-names>
         SW
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Incidental coronary artery calcification and stroke risk in patients with atrial fibrillation
      </article-title>
      <source>
       AJR. Am. J. Roentgenol.
      </source>
      <year>
       2020
      </year>
      <volume>
       215
      </volume>
      <fpage>
       344
      </fpage>
      <pub-id pub-id-type="doi">
       10.2214/AJR.19.22298
      </pub-id>
      <pub-id pub-id-type="pmid">
       32348185
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7447556
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR15">
     <label>
      15.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hylek
        </surname>
        <given-names>
         EM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2003
      </year>
      <volume>
       349
      </volume>
      <fpage>
       1019
      </fpage>
      <lpage>
       1026
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD3sXntlagtbY%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa022913
      </pub-id>
      <pub-id pub-id-type="pmid">
       12968085
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR16">
     <label>
      16.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Auer
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Stroke severity in patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists
      </article-title>
      <source>
       J. Neurol.
      </source>
      <year>
       2019
      </year>
      <volume>
       266
      </volume>
      <fpage>
       2263
      </fpage>
      <lpage>
       2272
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXhtFKhur3J
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1007/s00415-019-09412-y
      </pub-id>
      <pub-id pub-id-type="pmid">
       31165232
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR17">
     <label>
      17.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Park
        </surname>
        <given-names>
         JH
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Atherosclerotic burden and vascular risk in stroke patients with atrial fibrillation
      </article-title>
      <source>
       Stroke
      </source>
      <year>
       2021
      </year>
      <volume>
       52
      </volume>
      <fpage>
       1662
      </fpage>
      <lpage>
       1672
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXht1arsr3F
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1161/strokeaha.120.032232
      </pub-id>
      <pub-id pub-id-type="pmid">
       33794654
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR18">
     <label>
      18.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kodani
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Impact of blood pressure control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation: A subanalysis of the J-RHYTHM registry
      </article-title>
      <source>
       J. Am. Heart Assoc.
      </source>
      <year>
       2016
      </year>
      <volume>
       5
      </volume>
      <fpage>
       e004075
      </fpage>
      <pub-id pub-id-type="doi">
       10.1161/JAHA.116.004075
      </pub-id>
      <pub-id pub-id-type="pmid">
       27620886
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5079049
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR19">
     <label>
      19.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ding
        </surname>
        <given-names>
         WY
        </given-names>
       </name>
       <name>
        <surname>
         Protty
        </surname>
        <given-names>
         MB
        </given-names>
       </name>
       <name>
        <surname>
         Davies
        </surname>
        <given-names>
         IG
        </given-names>
       </name>
       <name>
        <surname>
         Lip
        </surname>
        <given-names>
         GYH
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Relationship between lipoproteins, thrombosis, and atrial fibrillation
      </article-title>
      <source>
       Cardiovasc. Res.
      </source>
      <year>
       2021
      </year>
      <volume>
       118
      </volume>
      <fpage>
       716
      </fpage>
      <lpage>
       731
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhvVOltbnM
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/cvr/cvab017
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8859639
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR20">
     <label>
      20.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Echouffo-Tcheugui
        </surname>
        <given-names>
         JB
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Care patterns and outcomes in atrial fibrillation patients with and without diabetes
      </article-title>
      <source>
       J. Am. Coll. Cardiol.
      </source>
      <year>
       2017
      </year>
      <volume>
       70
      </volume>
      <fpage>
       1325
      </fpage>
      <lpage>
       1335
      </lpage>
      <pub-id pub-id-type="doi">
       10.1016/j.jacc.2017.07.755
      </pub-id>
      <pub-id pub-id-type="pmid">
       28882229
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR21">
     <label>
      21.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Best
        </surname>
        <given-names>
         JG
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Antithrombotic dilemmas in stroke medicine: New data, unsolved challenges
      </article-title>
      <source>
       J. Neurol. Neurosurg. Psychiatry
      </source>
      <year>
       2022
      </year>
      <pub-id pub-id-type="doi">
       10.1136/jnnp-2020-325249
      </pub-id>
      <pub-id pub-id-type="pmid">
       35728935
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR22">
     <label>
      22.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Douros
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Concomitant use of direct oral anticoagulants with antiplatelet agents and the risk of major bleeding in patients with nonvalvular atrial fibrillation
      </article-title>
      <source>
       Am. J. Med.
      </source>
      <year>
       2019
      </year>
      <volume>
       132
      </volume>
      <fpage>
       191
      </fpage>
      <lpage>
       199.e112
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXit1yms7rO
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.amjmed.2018.10.008
      </pub-id>
      <pub-id pub-id-type="pmid">
       30691551
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR23">
     <label>
      23.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lou
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Meta-analysis comparing dual versus single antiplatelet therapy in combination with antithrombotic therapy in patients with atrial fibrillation who underwent percutaneous coronary intervention with stent implantation
      </article-title>
      <source>
       Am. J. Cardiol.
      </source>
      <year>
       2018
      </year>
      <volume>
       122
      </volume>
      <fpage>
       604
      </fpage>
      <lpage>
       611
      </lpage>
      <pub-id pub-id-type="doi">
       10.1016/j.amjcard.2018.04.050
      </pub-id>
      <pub-id pub-id-type="pmid">
       30205887
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR24">
     <label>
      24.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Deb
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A review of propensity-score methods and their use in cardiovascular research
      </article-title>
      <source>
       Can. J. Cardiol.
      </source>
      <year>
       2016
      </year>
      <volume>
       32
      </volume>
      <fpage>
       259
      </fpage>
      <lpage>
       265
      </lpage>
      <pub-id pub-id-type="doi">
       10.1016/j.cjca.2015.05.015
      </pub-id>
      <pub-id pub-id-type="pmid">
       26315351
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR25">
     <label>
      25.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Adams
        </surname>
        <given-names>
         HP
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment
      </article-title>
      <source>
       Stroke
      </source>
      <year>
       1993
      </year>
      <volume>
       24
      </volume>
      <fpage>
       35
      </fpage>
      <lpage>
       41
      </lpage>
      <pub-id pub-id-type="doi">
       10.1161/01.STR.24.1.35
      </pub-id>
      <pub-id pub-id-type="pmid">
       7678184
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR26">
     <label>
      26.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Grundy
        </surname>
        <given-names>
         SM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines
      </article-title>
      <source>
       Circulation
      </source>
      <year>
       2019
      </year>
      <volume>
       139
      </volume>
      <fpage>
       e1082
      </fpage>
      <lpage>
       e1143
      </lpage>
      <pub-id pub-id-type="doi">
       10.1161/CIR.0000000000000625
      </pub-id>
      <pub-id pub-id-type="pmid">
       30586774
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR27">
     <label>
      27.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <collab>
        NACET Collaborators
       </collab>
      </person-group>
      <article-title xml:lang="en">
       Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       1991
      </year>
      <volume>
       325
      </volume>
      <fpage>
       445
      </fpage>
      <lpage>
       453
      </lpage>
      <pub-id pub-id-type="doi">
       10.1056/NEJM199108153250701
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR28">
     <label>
      28.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Chimowitz
        </surname>
        <given-names>
         MI
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2005
      </year>
      <volume>
       352
      </volume>
      <fpage>
       1305
      </fpage>
      <lpage>
       1316
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD2MXislCjsLo%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa043033
      </pub-id>
      <pub-id pub-id-type="pmid">
       15800226
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR29">
     <label>
      29.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hicks
        </surname>
        <given-names>
         KA
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       2017 Cardiovascular and stroke endpoint definitions for clinical trials
      </article-title>
      <source>
       Circulation
      </source>
      <year>
       2018
      </year>
      <volume>
       137
      </volume>
      <fpage>
       961
      </fpage>
      <lpage>
       972
      </lpage>
      <pub-id pub-id-type="doi">
       10.1161/CIRCULATIONAHA.117.033502
      </pub-id>
      <pub-id pub-id-type="pmid">
       29483172
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR30">
     <label>
      30.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Crump
        </surname>
        <given-names>
         RK
        </given-names>
       </name>
       <name>
        <surname>
         Hotz
        </surname>
        <given-names>
         VJ
        </given-names>
       </name>
       <name>
        <surname>
         Imbens
        </surname>
        <given-names>
         GW
        </given-names>
       </name>
       <name>
        <surname>
         Mitnik
        </surname>
        <given-names>
         OA
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Dealing with limited overlap in estimation of average treatment effects
      </article-title>
      <source>
       Biometrika
      </source>
      <year>
       2009
      </year>
      <volume>
       96
      </volume>
      <fpage>
       187
      </fpage>
      <lpage>
       199
      </lpage>
      <pub-id assigning-authority="American Mathematical Society" pub-id-type="other">
       2482144
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/biomet/asn055
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR31">
     <label>
      31.
     </label>
     <mixed-citation publication-type="other">
      Team, R. C.
      <italic>
       R: A Language and Environment for Statistical Computing
      </italic>
      .
      <ext-link ext-link-type="uri" xlink:href="http://www.R-project.org">
       http://www.R-project.org
      </ext-link>
      (2014).
     </mixed-citation>
    </ref>
    <ref id="CR32">
     <label>
      32.
     </label>
     <mixed-citation publication-type="book">
      <person-group person-group-type="author">
       <name>
        <surname>
         Therneau
        </surname>
        <given-names>
         TM
        </given-names>
       </name>
       <name>
        <surname>
         Grambsch
        </surname>
        <given-names>
         PM
        </given-names>
       </name>
      </person-group>
      <source>
       Modeling Survival Data: Extending the Cox Model
      </source>
      <year>
       2000
      </year>
      <publisher-name>
       Springer
      </publisher-name>
      <pub-id pub-id-type="doi">
       10.1007/978-1-4757-3294-8
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR33">
     <label>
      33.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Zeng
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Li
        </surname>
        <given-names>
         F
        </given-names>
       </name>
       <name>
        <surname>
         Wang
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <name>
        <surname>
         Li
        </surname>
        <given-names>
         F
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Propensity score weighting for covariate adjustment in randomized clinical trials
      </article-title>
      <source>
       Stat. Med.
      </source>
      <year>
       2021
      </year>
      <volume>
       40
      </volume>
      <fpage>
       842
      </fpage>
      <lpage>
       858
      </lpage>
      <pub-id assigning-authority="American Mathematical Society" pub-id-type="other">
       4201106
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1002/sim.8805
      </pub-id>
      <pub-id pub-id-type="pmid">
       33174296
      </pub-id>
     </mixed-citation>
    </ref>
   </ref-list>
  </ref-list>
  <app-group>
   <app id="App1" specific-use="web-only">
    <sec id="Sec14">
     <title>
      Taarifa za Ziada
     </title>
     <p id="Par27">
      <supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary Information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41598_2023_51013_MOESM1_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Supplementary Information.
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
   </app>
  </app-group>
  <notes notes-type="ESMHint">
   <title>
    Taarifa za Ziada
   </title>
   <p>
    The online version contains supplementary material available at
    <ext-link ext-link-type="doi" xlink:href="10.1038/s41598-023-51013-3">
     https://doi.org/10.1038/s41598-023-51013-3
    </ext-link>
    .
   </p>
  </notes>
  <notes notes-type="Misc">
   <title>
    Tanbihi ya Mchapishaji
   </title>
   <p>
    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
   </p>
  </notes>
 </back>
</article>
